Strategic alliance with WuXi AppTec to develop next-generation biologics in China
New small molecule development facility; new global hub for Pharmaceutical Development
16 December 2015
AstraZeneca, along with MedImmune, its global biologics research and development arm, today announced a range of strategic initiatives to accelerate the delivery of innovative biologics and targeted medicines to patients in China, the company’s second largest market globally and a key growth platform. The initiatives and investments include:
- A strategic alliance with WuXi AppTec, a leading Chinese biologics manufacturer and contract research organisation, to produce innovative biologics locally in China. Under the agreement, AstraZeneca has the option to acquire WuXi AppTec’s biologics manufacturing capacity in Wuxi City in the next few years through an overall investment approximating $100 million. Prior to that, Wuxi AppTec remains the company’s exclusive partner for R&D manufacturing for innovative biologics in China.
This strategic alliance will bring cutting-edge research and technical capability for biologics to China with the aim of addressing unmet patient needs in AstraZeneca’s main therapy areas of respiratory, inflammation and autoimmunity; cardiovascular and metabolic diseases, and oncology. The alliance builds on the existing joint venture between MedImmune and WuXi AppTec to develop and commercialise MEDI5117, a novel biologic for autoimmune and inflammatory diseases, in China.
- An investment of $50 million to build an additional development and launch facility alongside our existing manufacturing site in Wuxi City to support the development and manufacture of innovative small molecules discovered in China and our global R&D sites.
- Additional investments include the creation of a new global hub for Pharmaceutical Development – alongside those in the UK and Sweden - with up to 50 scientists based in Shanghai and Wuxi City, to support both China and global needs. AstraZeneca is also establishing an integrated China medicines development organisation, bringing together early and late-stage medicines development across small molecules and biologics.
These investments and dedicated R&D capabilities are aimed at accelerating Chinese patients’ access to innovative medicines to address significant unmet need in AstraZeneca’s main therapy areas - respiratory, inflammation and autoimmunity; cardiovascular and metabolic diseases; and oncology. AstraZeneca’s commitment to bring cutting-edge biopharmaceutical science to China and to partner with the local science community is aligned with the Chinese Government’s focus on increasing innovation to support economic development and access to healthcare.
Bahija Jallal, Executive Vice President, MedImmune, said: "We are delighted to broaden our collaboration with WuXi AppTec, a company with strong leadership in the Chinese biopharmaceutical sector, to address the healthcare needs of local patients. This strategic alliance, alongside our accelerated investments will create a sustainable and strategic innovation platform in China and strengthen our leadership in developing next-generation biologics for both local needs and patients around the world."
Mark Mallon, Executive Vice President, International, AstraZeneca, said: “Our increased investment reinforces our commitment to bring innovative medicines from our exciting pipeline of targeted and biological medicines to patients in China faster and supports our continued strong growth in the country. These initiatives will allow us to better integrate the needs of this important market into our global portfolio decisions and make us the first multinational biopharmaceutical company to create a dedicated R&D platform and manufacturing capabilities in China for local development from research through to commercialisation.”
NOTES TO EDITORS
About WuXi AppTec
WuXi AppTec, an operating subsidiary of WuXi PharmaTech, is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the US. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. WuXi PharmaTech’s services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information on WuXi’s biologics services, please visit: www.wuxiapptec.com/biologics.html.
About AstraZeneca in China
Since entering China in 1993, AstraZeneca has been committed to continuously following the science, focusing on innovation and becoming one of the most trusted healthcare partners in improving the lives of Chinese patients. AstraZeneca’s China headquarters are based in Shanghai, and the company has more than 11,000 employees throughout the country. We’ve established manufacturing sites in Wuxi and Taizhou, as well as a China Distribution Centre in Wuxi. AstraZeneca also has an Innovation Centre in Shanghai, focused on the discovery and development of innovative candidate drugs to address the unique needs of patients in Asia.
MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centres. For more information, please visit www.medimmune.com.
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.
|Esra Erkal-Paler||UK/Global||+44 20 7604 8030|
|Neil Burrows||UK/Global||+44 20 7604 8032|
|Vanessa Rhodes||UK/Global||+44 20 7604 8037|
|Karen Birmingham||UK/Global||+44 20 7604 8120|
|Jacob Lund||Sweden||+46 8 553 260 20|
|Michele Meixell||US||+1 302 885 2677|
|Thomas Kudsk Larsen||Oncology||+44 7818 524185|
|Eugenia Litz||RIA||+44 7884 735627|
|Nick Stone||CVMD||+44 7717 618834|
|Craig Marks||Finance||+44 7881 615764|
|Christer Gruvris||Consensus Forecasts||+44 7827 836825|
|Lindsey Trickett||Oncology, ING||+1 240 543 7970|
|Mitch Chan||Oncology||+1 240 477 3771|
|Dial / Toll-Free||+1 866 381 7277|
Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease,
ING - Infection, Neuroscience and Gastrointestinal